MedTrace Logo

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

NCT00726427 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects

Conditions

  • Healthy

Interventions

DRUG

AZD1656

Dose escalation to achieve maximum tolerated dose

DRUG

AZD1656

Oral single dose

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD · AstraZeneca R&D Mölndal

  • Sylvan Hurewitz, MD · AstraZeneca CPU, Philadelphia, PA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726427 on ClinicalTrials.gov